Pfizer/$PFE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Employees
81,000
Headquarters
Website
Pfizer Metrics
BasicAdvanced
$136B
12.60
$1.89
0.46
$1.71
7.21%
Price and volume
Market cap
$136B
Beta
0.46
52-week high
$29.73
52-week low
$20.92
Average daily volume
43M
Dividend rate
$1.71
Financial strength
Current ratio
1.158
Quick ratio
0.778
Long term debt to equity
64.858
Total debt to equity
69.703
Dividend payout ratio (TTM)
89.68%
Interest coverage (TTM)
6.26%
Profitability
EBITDA (TTM)
24,506
Gross margin (TTM)
73.82%
Net profit margin (TTM)
16.84%
Operating margin (TTM)
27.78%
Effective tax rate (TTM)
-2.23%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
5.25%
Return on equity (TTM)
12.17%
Valuation
Price to earnings (TTM)
12.603
Price to revenue (TTM)
2.121
Price to book
1.53
Price to tangible book (TTM)
-4.11
Price to free cash flow (TTM)
10.887
Free cash flow yield (TTM)
9.19%
Free cash flow per share (TTM)
2.192
Dividend yield (TTM)
7.16%
Forward dividend yield
7.21%
Growth
Revenue change (TTM)
13.53%
Earnings per share change (TTM)
-504.04%
3-year revenue growth (CAGR)
-14.26%
10-year revenue growth (CAGR)
2.85%
3-year earnings per share growth (CAGR)
-28.16%
10-year earnings per share growth (CAGR)
3.00%
3-year dividend per share growth (CAGR)
2.47%
10-year dividend per share growth (CAGR)
4.64%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Bulls say / Bears say
Pfizer raised its 2025 full-year adjusted profit forecast to $2.90–$3.10 per share after second-quarter revenue of $14.65 billion beat Wall Street forecasts by more than $1 billion, showing steady demand and strong operations (Reuters).
Core products Vyndaqel and Eliquis both surpassed analyst expectations in Q2, with Vyndaqel bringing in $1.62 billion and Eliquis generating $2.0 billion, driving overall revenue and boosting margins (Reuters).
The European Commission approved Pfizer’s Abrysvo RSV vaccine for adults aged 18–59 at increased risk, expanding the company’s market presence and putting it ahead of GSK in the EU RSV market (Reuters).
Pfizer faces a looming “patent cliff,” with more than $180 billion in annual drug revenues, including key Pfizer products, set to lose patent protection by 2027–2028, putting the company at risk for steep revenue losses from generic competition (FT).
Pfizer ended development of its danuglipron obesity pill program due to safety concerns, which means it is falling behind in the fast-growing GLP-1 weight-loss market now dominated by Eli Lilly and Novo Nordisk (Reuters).
Persistent political pressure in the U.S. to lower drug prices, combined with threatened 15% tariffs on EU imports—concerns raised by CEO Albert Bourla—could compress profit margins and drive up manufacturing costs (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine
New York Post3 days ago
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Market Watch3 days ago
Trump officials to link child deaths to covid shots, according to reports
CNBC Television3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $136B as of September 15, 2025.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 12.6 as of September 15, 2025.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $1.71 and the yield is 7.21%. Pfizer has a payout ratio of 89.68% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment date is unconfirmed.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.